Weibin Bao

2.1k total citations
27 papers, 1.3k citations indexed

About

Weibin Bao is a scholar working on Rheumatology, Epidemiology and Hepatology. According to data from OpenAlex, Weibin Bao has authored 27 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 8 papers in Epidemiology and 8 papers in Hepatology. Recurrent topics in Weibin Bao's work include Spondyloarthritis Studies and Treatments (10 papers), Hepatitis C virus research (8 papers) and Hepatitis B Virus Studies (7 papers). Weibin Bao is often cited by papers focused on Spondyloarthritis Studies and Treatments (10 papers), Hepatitis C virus research (8 papers) and Hepatitis B Virus Studies (7 papers). Weibin Bao collaborates with scholars based in United States, Switzerland and Germany. Weibin Bao's co-authors include Angel FowlerTaylor, Stephen T. Holgate, John V. Fahy, Monica Kraft, Nizar N. Jarjour, Susan J. Wilson, Kian Fan Chung, Ratko Djukanović, John G. Matthews and William W. Busse and has published in prestigious journals such as Circulation, Hepatology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Weibin Bao

26 papers receiving 1.2k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Weibin Bao	560	476	454	399	243	27	1.3k
P Elling	58 0.1×	331 0.7×	236 0.5×	314 0.8×	69 0.3×	49	971
Matthieu Groh	106 0.2×	143 0.3×	16 0.0×	214 0.5×	30 0.1×	53	655
Dominic Mallon	79 0.1×	167 0.4×	18 0.0×	84 0.2×	89 0.4×	21	636
P Stock	112 0.2×	76 0.2×	87 0.2×	63 0.2×	40 0.2×	15	505
Neil Snowden	42 0.1×	168 0.4×	81 0.2×	42 0.1×	24 0.1×	41	919
А. Смаил	147 0.3×	87 0.2×	22 0.0×	197 0.5×	18 0.1×	47	590
Farideh Khosravi	55 0.1×	143 0.3×	27 0.1×	57 0.1×	18 0.1×	55	797
Gabriela de Larrañaga	47 0.1×	153 0.3×	48 0.1×	31 0.1×	27 0.1×	47	816
Yoshinori Kogata	38 0.1×	283 0.6×	27 0.1×	88 0.2×	20 0.1×	13	950
Takefumi Saito	163 0.3×	241 0.5×	10 0.0×	416 1.0×	16 0.1×	84	743

Countries citing papers authored by Weibin Bao

Since Specialization

Citations

This map shows the geographic impact of Weibin Bao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weibin Bao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weibin Bao more than expected).

Fields of papers citing papers by Weibin Bao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weibin Bao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weibin Bao. The network helps show where Weibin Bao may publish in the future.

Co-authorship network of co-authors of Weibin Bao

This figure shows the co-authorship network connecting the top 25 collaborators of Weibin Bao. A scholar is included among the top collaborators of Weibin Bao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weibin Bao. Weibin Bao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lebwohl, Mark, Alice B. Gottlieb, Philip J. Mease, et al.. (2024). Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials. Dermatology and Therapy. 14(3). 729–743. 4 indexed citations

Felten, Renaud, et al.. (2023). Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies. RMD Open. 9(4). e003428–e003428. 4 indexed citations

Coates, Laura C., Philip J. Mease, Dafna D. Gladman, et al.. (2023). Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study. RMD Open. 9(2). e002939–e002939. 2 indexed citations

Conaghan, Philip G., Maria Antonietta D’Agostino, Maarten Boers, et al.. (2023). E087 Reduced joint synovitis assessment versus the global EULAR OMERACT synovitis score (GLOESS) to predict the response to secukinumab in patients with active psoriatic arthritis and inadequate response to conventional disease-modifying anti-rheumatic drugs: exploratory results from the ULTIMATE trial. Lara D. Veeken. 62(Supplement_2).

D’Agostino, Maria Antonietta, Philippe Carron, Corine Gaillez, et al.. (2023). Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension. Seminars in Arthritis and Rheumatism. 63. 152259–152259. 10 indexed citations

Gottlieb, Alice B., Atul Deodhar, Iain B. McInnes, et al.. (2022). Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Acta Dermato Venereologica. 102. adv00698–adv00698. 57 indexed citations

Magnolo, Nina, Külli Kingo, Vivian Laquer, et al.. (2022). Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study. Pediatric Drugs. 24(4). 377–387. 11 indexed citations

Horst‐Bruinsma, Irene van der, Corinne Miceli‐Richard, Jürgen Braun, et al.. (2021). A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis. Rheumatology and Therapy. 8(4). 1775–1787. 10 indexed citations

Gottlieb, Alice B., Joseph F. Merola, Kristian Reich, et al.. (2021). 26248 Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with moderate-to-severe plaque psoriasis: Results from the EXCEED study. Journal of the American Academy of Dermatology. 85(3). AB92–AB92. 1 indexed citations

10.

Senni, Michele, Rolf Wachter, Klaus K. Witte, et al.. (2019). Initiation of Sacubitril/Valsartan Shortly After Hospitalisation for Acutely Decompensated Heart Failure in Patients with Newly Diagnosed ( de novo ) Heart Failure: A Subgroup Analysis of the TRANSITION Study. European Journal of Heart Failure. 22(2). 303–312. 43 indexed citations

11.

Pascual‐Figal, Domingo A., Michele Senni, Jan Bělohlávek, et al.. (2018). Abstract 15567: Short-Term Effect on Cardiac Biomarkers of Initiation of Sacubitril/Valsartan in Hospitalized Patients With Heart Failure and Reduced Ejection Fraction: Results of the Transition Study. Circulation. 2 indexed citations

12.

Hou, Jinlin, Guangfeng Shi, Mobin Wan, et al.. (2015). Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. Advances in Therapy. 32(8). 727–741. 18 indexed citations

13.

Marcellin, Patrick, Karsten Wursthorn, Heiner Wedemeyer, et al.. (2014). Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. Journal of Hepatology. 62(1). 41–47. 41 indexed citations

14.

Jia, Jidong, Jinlin Hou, Deming Tan, et al.. (2013). Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. Hepatology International. 8(1). 72–82. 13 indexed citations

15.

Gane, Edward, Yuming Wang, Yun‐Fan Liaw, et al.. (2011). Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver International. 31(5). 676–684. 37 indexed citations

16.

Wursthorn, Karsten, Antonio Riva, Zachary Goodman, et al.. (2010). Kinetics of Hepatitis B Surface Antigen Decline During 3 Years of Telbivudine Treatment in Hepatitis B e Antigen–Positive Patients. Hepatology. 52(5). 1611–1620. 170 indexed citations

17.

Zeuzem, Stefan, Edward Gane, Yun‐Fan Liaw, et al.. (2009). Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B. Journal of Hepatology. 51(1). 11–20. 156 indexed citations

18.

Чучалин, А. Г., Kai Richter, Norbert Krug, et al.. (2007). Safety and tolerability of indacaterol in asthma: A randomized, placebo-controlled 28-day study. Respiratory Medicine. 101(10). 2065–2075. 36 indexed citations

19.

Beier, Jutta, Pascal Chanez, Jean‐Benoît Martinot, et al.. (2006). Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial. Pulmonary Pharmacology & Therapeutics. 20(6). 740–749. 67 indexed citations

20.

Djukanović, Ratko, Susan J. Wilson, Monica Kraft, et al.. (2004). Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma. American Journal of Respiratory and Critical Care Medicine. 170(6). 583–593. 498 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact